How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32554552.
- Also identified by DOI 10.1158/0008-5472.CAN-20-1420 and PMC identifier 7541560.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. While tumor antigens are needed for effective immunotherapy, a favorable tumor immune microenvironment is also critical. In this review, we discuss emerging evidence that tumor cells exploit cellular plasticity and dedifferentiation programs to avoid immune surveillance, which in turn drives metastatic dissemination and resistance to immunotherapy. A deeper understanding of these programs may provide novel opportunities to enhance the efficacy of existing immunotherapies.
Medical subject headings
- Cell Dedifferentiation
- Neoplasms
- Tumor Escape